Article Text

Download PDFPDF

Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy
Free
  1. R Lakshman1,
  2. C Murdoch1,
  3. G Race1,
  4. R Burkinshaw1,
  5. L Shaw1,
  6. A Finn2
  1. 1Sheffield Institute for Vaccine Studies, Sheffield Children’s Hospital, Sheffield S10 2TH, UK
  2. 2Institute of Child Health, University of Bristol, Bristol BS2 8AE, UK
  1. Correspondence to:
    Prof. A Finn, Institute of Child Health, Level 6, UBHT Education Centre, Upper Maudlin St, Bristol BS2 8AE, UK;
    Adam.Finn{at}bristol.ac.uk

Abstract

Aims: To ascertain whether the reduction in nasopharyngeal carriage of vaccine serotypes induced by pneumococcal conjugate vaccine (PnCV) administered to infants persists beyond the age of 2 years.

Methods: Non-randomised, unblinded controlled study of 2–5 year old children who had received three doses of heptavalent PnCV (7VPnCV) in infancy and 23-valent pneumococcal polysaccharide vaccine at 13 months, and unimmunised controls. Nasopharyngeal swabs were taken in summer (150 vaccinated subjects, 126 controls) and winter (143 vaccinated subjects, 188 controls). The swabs were cultured and serotyped for Streptococcus pneumoniae.

Results: Carriage rates (vaccinated subjects: 24.7% and 43.4%; controls: 27.0% and 41.0%, in summer and winter respectively) and carriage of vaccine serotypes (subjects: 10.0% and 30.0%; controls: 13.5% and 31.5%, in summer and winter respectively) were similar in the two groups.

Conclusions: Effects of vaccination in infancy on rates of nasal carriage of pneumococcus and serotype replacement in children living in a largely unvaccinated population are no longer evident by 2–5 years of age.

  • pneumococcal vaccine
  • nasopharyngeal carriage
  • 7VPnCV, heptavalent pneumococcal conjugate vaccine
  • Hib, Haemophilus influenzae type b vaccine
  • NP, nasopharyngeal
  • STGG, skimmed milk powder-tryptone-glycerol-glucose
View Full Text

Statistics from Altmetric.com

Footnotes

  • The study was funded by a grant from Wyeth Lederle Vaccines, UK

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Atoms
    Nick Mann